Ultragenyx Pharmaceutical’s updated fair value estimate now sits at US$52.05 per share, a slight change from the prior US$52.45 target that reframes expectations around the stock. This move comes as ...

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) is one of the 10 most promising mid-cap healthcare stocks according to hedge ...

It has been about a month since the last earnings report for Ultragenyx (RARE). Shares have lost about 13.6% in that time frame, underperforming the S&P 500. But investors have to be wondering, will ...

Ultragenyx Pharmaceutical stock has plummeted this week, after its experimental treatment for an uncommon genetic bone disease failed in late-stage trials. But Wall Street analysts say there is still ...

Ultragenyx Pharmaceutical ( (RARE)) has issued an announcement. At its Annual Meeting of Stockholders held on May 14, 2026, Ultragenyx Pharmaceutical shareholders approved the Third Amended and ...

Ultragenyx is a biopharmaceutical company committed to bringing novel products to patients for the treatment of serious rare and ultra-rare genetic diseases. The company has built a diverse portfolio ...

The MarketWatch News Department was not involved in the creation of this content. Neither study achieved its primary endpoint of reduction in annualized clinical fracture rate compared to placebo ...

According to TheFly.com, Burnett informed investors in a research note that the stock now features a favorable risk-reward profile, anticipating feedback from the Food and Drug Administration (FDA) ...

Heading into 2026 on an inauspicious note, UltragenyxPharmaceuticals (NASDAQ: RARE), a pharmaceutical company specializing in treatments for rare and ultra-rare genetic diseases, announced ...

JPMorgan on Thursday shared updated thoughts on Ultragenyx Pharmaceutical Inc’s RARE setrusumab program in osteogenesis imperfecta (OI). In a fourth-quarter 2024 press release, the company said ...